GH Research PLC Trial Data Accepted at ACNP Meeting
Ticker: GHRS · Form: 6-K · Filed: Oct 17, 2025 · CIK: 1855129
Sentiment: neutral
Topics: clinical-trial, conference-presentation, drug-development
TL;DR
GH Research's GH001 trial data accepted for presentation at major ACNP meeting in Jan 2026.
AI Summary
GH Research PLC announced on October 17, 2025, that abstracts related to its GH001-TRD-201 clinical trial have been accepted for presentation at the 64th American College of Neuropsychopharmacology (ACNP) annual meeting. The congress is scheduled for January 12-15, 2026, in Nassau, Bahamas, and will feature presentations by Sanjay J. Mathew and Lisa Harding.
Why It Matters
The acceptance of trial data at a major neuropsychopharmacology conference indicates progress and potential validation of GH Research's drug candidate, GH001, which could impact its future development and market perception.
Risk Assessment
Risk Level: low — This filing is an announcement of accepted abstracts for a conference, which is standard disclosure and does not represent a significant change in the company's financial or operational status.
Key Players & Entities
- GH Research PLC (company) — Registrant
- GH001-TRD-201 (clinical_trial) — Clinical trial name
- 64th American College of Neuropsychopharmacology (ACNP) annual meeting (conference) — Event where data will be presented
- January 12-15, 2026 (date) — Date of the ACNP meeting
- Sanjay J. Mathew (person) — Presenter of abstract
- Lisa Harding (person) — Presenter of abstract
FAQ
What is the specific indication being studied in the GH001-TRD-201 clinical trial?
The filing does not specify the indication for the GH001-TRD-201 clinical trial, only that abstracts related to it were accepted for the ACNP meeting.
When will the full results of the GH001-TRD-201 trial be presented?
The filing states that abstracts have been accepted for presentation at the ACNP meeting from January 12-15, 2026; it does not specify if full results will be presented or when.
What is the significance of the ACNP annual meeting?
The ACNP annual meeting is described as a major congress for neuropsychopharmacology, indicating it is a significant event for presenting research in this field.
Are there any financial implications mentioned in this announcement?
No financial amounts or implications are mentioned in this announcement; it solely concerns the acceptance of trial data for presentation.
Where is GH Research PLC headquartered?
GH Research PLC is headquartered in Dublin, Ireland, with its principal executive office located at Joshua Dawson House, Dawson Street, Dublin 2, D02 RY95.
Filing Stats: 353 words · 1 min read · ~1 pages · Grade level 12.1 · Accepted 2025-10-17 07:03:03
Filing Documents
- ef20057307_6k.htm (6-K) — 12KB
- ef20057307_ex99-1.htm (EX-99.1) — 14KB
- ef20057307_ex99-2.htm (EX-99.2) — 15KB
- ef20057307_ex99-3.htm (EX-99.3) — 12KB
- 0001140361-25-038374.txt ( ) — 54KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2025. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F Form 40-F GH Research PLC announces the acceptance of posters related to its GH001-TRD-201 clinical trial at the 64 th American College of Neuropsychopharmacology (ACNP) annual meeting (the " Congress "), which is scheduled to take place from January 12-15, 2026, in Nassau, Bahamas. A copy of the abstract for the poster to be presented by Sanjay J. Mathew during the Congress is attached hereto as Exhibit 99.1. A copy of the abstract for the poster to be presented by Lisa Harding during the Congress is attached hereto as Exhibit 99.2. A copy of the abstract for the poster to be presented by Andreas Reif during the Congress, is attached hereto as Exhibit 99.3. 1 EXHIBIT INDEX 99.1 Abstract for poster to be presented by Sanjay J. Mathew with Title: Suicidal Ideation and Behavior in Patients With Treatment-Resistant Depression Treated With GH001 99.2 Abstract for poster to be presented by Lisa Harding with Title: Rapid Antidepressant Effects of Inhaled GH001 in Treatment-Resistant Depression: Results from a Phase 2b, Double-Blind, Randomized Controlled Trial with 6-Month Follow-Up 99.3 Abstract for poster to be presented by Andreas Reif with Title: Efficacy and Safety of Inhaled Mebufotenin (GH001) in Patients with Bipolar II Disorder and a Current Major Depressive Episode: Results from a Phase 2a Clinical Trial 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. GH Research PLC Date: October 17, 2025 By: /s/ Julie Ryan Name: Julie Ryan Title: Vice President, Finance 3